The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial

doi:10.1186/1546-0096-8-24

Research

The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial

Sudha Visvanathan, Carrie Wagner, Joseph C Marini, Daniel J Lovell, Alberto Martini, Ross Petty, Ruben Cuttica, Patricia Woo, Graciela Espada, Marco Gattorno, Maria T Apaz, Eileen Baildam, Anders Fasth, Valeria Gerloni, Pekka Lahdenne, Pierre Quartier, Rotraud Saurenmann, Suzanne Travers, Alan Mendelsohn, Stephen Xu, Edward H Giannini, Nicolino Ruperto^*, the Paediatric Rheumatology INternational Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)

* Corresponding author: Nicolino Ruperto nicolaruperto@ospedale-gaslini.ge.it

Pediatric Rheumatology 2010, 8:24 doi:10.1186/1546-0096-8-24

No comments have yet been made on this article.

Pediatric Rheumatology

Viewing options

Associated material

Tools

Share this article

The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial

Pediatric Rheumatology

Viewing options

Associated material

Related literature

Cited by

Other articles by authors

Related articles/pages

Tools

Share this article

The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial